Recent advances in the clinical targeting of hedgehog/GLI signaling in cancer

Hao Xie, Brooke D. Paradise, Wen Wee Ma, Martin E. Fernandez-Zapico

Research output: Contribution to journalReview articlepeer-review


The Hedgehog/GLI signaling pathway plays an important role in normal embryonic tissue development and has been implicated in the pathogenesis of various human cancers. In this review article, we summarize pre-clinical evidence supporting the suitability of targeting this signaling pathway in cancers. We review agents blocking both the ligand-dependent and ligand-independent cascades, and discuss the clinical evidence, which has led to the FDA approval of Hedgehog receptor Smoothened inhibitors, vismodegib, and sonidegib, in different malignancies. Finally, we provide an overview of published and ongoing clinical trial data on single agent or combination therapeutic strategies, targeting Hedgehog/GLI signaling pathway, in both advanced solid tumors and hematologic malignancies.

Original languageEnglish (US)
Article number394
Issue number5
StatePublished - May 2019


  • Clinical trials
  • GLI factors
  • Hedgehog
  • Smoothened
  • Sonidegib
  • Vismodegib

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Recent advances in the clinical targeting of hedgehog/GLI signaling in cancer'. Together they form a unique fingerprint.

Cite this